At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OS OneStream, Inc.
Trading 12-22 14:38:52 EST
19.23
+0.81
+4.40%
High19.40Low18.38Vol606.69K
Open18.45D1 Closing18.42Amplitude5.54%
Mkt Cap4.71BTradable Cap4.24BTotal Shares244.98M
T/O11.64MT/O Rate0.27%Tradable Shares220.70M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

OneStream Chief Revenue Officer Ken Hohenstein Reports Sale of Common Shares
Reuters  ·  12-19
OneStream Chief Revenue Officer Ken Hohenstein Reports Sale of Common Shares
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
GlobeNewswire  ·  12-18
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
Meta's stock could soar in the next 6 months, along with these under-the-radar picks
Dow Jones  ·  12-18
Meta's stock could soar in the next 6 months, along with these under-the-radar picks
OneStream Coverage Assumed by BTIG at Buy
Dow Jones  ·  12-17
OneStream Coverage Assumed by BTIG at Buy
OneStream CFO William Koefoed Reports Sale of Common Shares
Reuters  ·  12-17
OneStream CFO William Koefoed Reports Sale of Common Shares
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Benzinga_recent_news  ·  12-13
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease
Benzinga_recent_news  ·  12-12
Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease
InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
GlobeNewswire  ·  12-11
InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
Is OneStream’s 41.6% Slide in 2025 Creating a Long Term Opportunity?
Simply Wall St.  ·  12-10
Is OneStream’s 41.6% Slide in 2025 Creating a Long Term Opportunity?
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
GlobeNewswire  ·  12-09
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
GlobeNewswire  ·  12-09
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
GlobeNewswire  ·  12-09
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
GlobeNewswire  ·  12-09
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Why Is Arcellx Stock Surging Today?
Benzinga  ·  12-09
Why Is Arcellx Stock Surging Today?
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
GlobeNewswire  ·  12-08
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire  ·  12-08
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
GlobeNewswire  ·  12-08
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
GlobeNewswire  ·  12-08
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study
prnewswire  ·  12-08
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
GlobeNewswire  ·  12-07
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Introduction

Company Name.
OneStream, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--